The Market Signal was created as a platform to help investors, if you own (NYSE:MRTX), (NASDAQ:GNTX) or (NASDAQ:SYNH) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.
https://themarketsignal.com/ Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)
Mirati Therapeutics Reports Q2 2020 Results
https://themarketsignal.com/Free-Report/MRTX
(Click link above or copy, paste and hit enter in your browser for your report)
Mirati Therapeutics Inc. (NYSE:MRTX) is trading above its Parabolic SAR of $146.10, thus the stock looks bullish. The company has announced its Q2 2020 financial results in which it didn't earn collaboration and licenses revenues but earned $0.3 million in license and collaboration revenues in 1H 2020. A year ago the company earned 0.6 million and $1.8 million in license and collaboration revenues in Q2 and 1H respectively. Net loss in Q2 2020 was $82.9 million or $1.89 per share whole for 1H 2020 net loss was $169.5 million or $3.91 per share.
Recently the company entered a partnership with Strata Oncology Inc. to broaden enrollment in the MRTX849 phase1/2 study in KRAS G12C mutation cancer patients.
Gentex Declares Quarterly Dividend Of $0.12 Per Share
https://themarketsignal.com/Free-Report/GNTX
(Click link above or copy, paste and hit enter in your browser for your report)
Gentex Corporation (NASDAQ:GNTX) is currently looking bullish and trades above its Parabolic SAR of $26.80. The Zeeland Michigan based company which supplies the digital vision, dimmable glass, connected car, and fire protection tech has announced that its board has declared a quarterly dividend of $0.12 per share. The dividend will be payable to shareholders on October 21, 2020, for those who will be on record as of October 9, 2020.
Syneos Health announces a commercial partnership with Indorsia
https://themarketsignal.com/Free-Report/SYNH
(Click link above or copy, paste and hit enter in your browser for your report)
Another bullish looking stock is Syneos Health Inc. (NASDAQ:SYNH) which is currently trading above its Parabolic SAR of $58.52. The company has entered a commercial partnership with Idorsia Ltd for the commercialization of Idorsia's new orexin receptor antagonist, daridorexant which is being studied for Insomnia treatment. The partnership brings Idorsia's daridorexant and the experience in the science of the orexin system with the robust consumer-facing sales expertise of Syneos Health to launch the product in the US.
In Q2 the company reported revenue of $1.013 billion which was a 13.1% decline from last year. GAAP net income was $3.9 million or $0.04 per share while adjusted earnings were $0.58 per share. For FY2020 the company expects revenue of $4.47 billion to 4.57 billion and adjusted EBITDA of $600 million-640 million.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.
We will get back to you within 24 hours.
COMTEX_370475481/2700/2020-09-01T08:29:46
Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.
